232 related articles for article (PubMed ID: 8017843)
1. Molecular interrelationships in multidrug resistance (review).
Kellen JA
Anticancer Res; 1994; 14(2A):433-5. PubMed ID: 8017843
[TBL] [Abstract][Full Text] [Related]
2. The reversal of multidrug resistance in cancer (review).
Kellen JA
Anticancer Res; 1993; 13(4):959-61. PubMed ID: 8352566
[TBL] [Abstract][Full Text] [Related]
3. Gene amplification as a target for cancer chemotherapy.
Snapka RM
Oncol Res; 1992; 4(4-5):145-50. PubMed ID: 1504374
[TBL] [Abstract][Full Text] [Related]
4. p53 and response to chemotherapy and radiotherapy.
Ruley HE
Important Adv Oncol; 1996; ():37-56. PubMed ID: 8791127
[No Abstract] [Full Text] [Related]
5. Apoptosis and cancer chemotherapy.
Chresta CM; Arriola EL; Hickman JA
Behring Inst Mitt; 1996 Oct; (97):232-40. PubMed ID: 8950479
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance, the last frontier?
Kellen JA
Anticancer Res; 1991; 11(2):917-9. PubMed ID: 1676582
[TBL] [Abstract][Full Text] [Related]
7. Carcinogenesis and the response of tumours to anticancer drugs.
Keith WN; Brown R
Anticancer Res; 1991; 11(5):1739-43. PubMed ID: 1768046
[TBL] [Abstract][Full Text] [Related]
8. The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
Petty RD
Clin Oncol (R Coll Radiol); 1996; 8(3):186-9. PubMed ID: 8814375
[No Abstract] [Full Text] [Related]
9. Cellular maturation and oncogene expression during drug-induced differentiation in vitro: a brief review.
Biedler JL; Spengler BA; Ross RA
Prog Clin Biol Res; 1990; 354A():287-312. PubMed ID: 2247493
[No Abstract] [Full Text] [Related]
10. Multidrug resistance.
Shibata H; Kanamaru R; Sato T; Ishioka C; Suzuki T; Wakui A
Sci Rep Res Inst Tohoku Univ Med; 1990 Dec; 37(1-4):27-50. PubMed ID: 2103657
[No Abstract] [Full Text] [Related]
11. [Tumor suppressor p53 gene: a potential target for cancer therapy?].
Soussi T
Bull Cancer; 1997 Jul; 84(7):753-6. PubMed ID: 9339203
[No Abstract] [Full Text] [Related]
12. Cancer chemotherapy. Progress in understanding multidrug resistance.
Stark GR
Nature; 1986 Dec 4-10; 324(6096):407-8. PubMed ID: 2878367
[No Abstract] [Full Text] [Related]
13. Multidrug resistance and behavioural phenotype of cancer cells.
Bashir I; Sikora K; Foster CS
Cell Biol Int; 1993 Oct; 17(10):907-17. PubMed ID: 8287021
[TBL] [Abstract][Full Text] [Related]
14. [P53 mutations, asset or disadvantage for cancer chemotherapy].
Jacquemin-Sablon A
Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
[TBL] [Abstract][Full Text] [Related]
15. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
Farrell NP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
[TBL] [Abstract][Full Text] [Related]
16. Gene amplification, drug resistance, and cancer.
Schimke RT
Cancer Res; 1984 May; 44(5):1735-42. PubMed ID: 6713376
[No Abstract] [Full Text] [Related]
17. Dominant oncogenes, tumor suppressors, and radiosensitivity.
Chiarugi V; Magnelli L; Cinelli M; Turchetti A; Ruggiero M
Cell Mol Biol Res; 1995; 41(3):161-6. PubMed ID: 8589756
[TBL] [Abstract][Full Text] [Related]
18. Transcription factors and drug resistance.
Kohno K; Uchiumi T; Niina I; Wakasugi T; Igarashi T; Momii Y; Yoshida T; Matsuo K; Miyamoto N; Izumi H
Eur J Cancer; 2005 Nov; 41(16):2577-86. PubMed ID: 16209921
[TBL] [Abstract][Full Text] [Related]
19. The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
Goldie JH; Coldman AJ
Cancer Res; 1984 Sep; 44(9):3643-53. PubMed ID: 6744284
[TBL] [Abstract][Full Text] [Related]
20. Oncogenes and tumor suppressor genes as paradigms in oncogenesis.
Spandidos DA
J BUON; 2007 Sep; 12 Suppl 1():S9-12. PubMed ID: 17935284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
